GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Cyclically Adjusted PB Ratio

Alnylam Pharmaceuticals (BSP:A1LN34) Cyclically Adjusted PB Ratio : 12.79 (As of May. 01, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-01), Alnylam Pharmaceuticals's current share price is R$36.84. Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was R$2.88. Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 12.79.

The historical rank and industry rank for Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

BSP:A1LN34' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.66   Med: 12.85   Max: 25.16
Current: 11.67

During the past years, Alnylam Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 25.16. The lowest was 4.66. And the median was 12.85.

BSP:A1LN34's Cyclically Adjusted PB Ratio is ranked worse than
92.08% of 644 companies
in the Biotechnology industry
Industry Median: 1.74 vs BSP:A1LN34: 11.67

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Alnylam Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was R$-0.430. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$2.88 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.02 11.59 13.79 18.66 15.53

Alnylam Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.66 15.73 15.04 14.11 15.53

Competitive Comparison of Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=36.84/2.88
=12.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Alnylam Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.43/129.4194*129.4194
=-0.430

Current CPI (Dec. 2023) = 129.4194.

Alnylam Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 1.471 99.695 1.910
201406 1.380 100.560 1.776
201409 1.379 100.428 1.777
201412 1.602 99.070 2.093
201503 2.791 99.621 3.626
201506 2.593 100.684 3.333
201509 3.045 100.392 3.925
201512 2.884 99.792 3.740
201603 2.573 100.470 3.314
201606 2.197 101.688 2.796
201609 1.925 101.861 2.446
201612 1.796 101.863 2.282
201703 1.510 102.862 1.900
201706 2.018 103.349 2.527
201709 1.795 104.136 2.231
201712 2.920 104.011 3.633
201803 2.864 105.290 3.520
201806 3.039 106.317 3.699
201809 3.007 106.507 3.654
201812 2.499 105.998 3.051
201903 2.792 107.251 3.369
201906 3.049 108.070 3.651
201909 2.973 108.329 3.552
201912 2.632 108.420 3.142
202003 2.914 108.902 3.463
202006 3.140 108.767 3.736
202009 2.825 109.815 3.329
202012 2.245 109.897 2.644
202103 2.224 111.754 2.576
202106 1.809 114.631 2.042
202109 1.670 115.734 1.867
202112 1.384 117.630 1.523
202203 0.827 121.301 0.882
202206 0.367 125.017 0.380
202209 -0.144 125.227 -0.149
202212 -0.335 125.222 -0.346
202303 -0.543 127.348 -0.552
202306 -0.793 128.729 -0.797
202309 -0.326 129.860 -0.325
202312 -0.430 129.419 -0.430

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alnylam Pharmaceuticals  (BSP:A1LN34) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals (BSP:A1LN34) Business Description

Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (BSP:A1LN34) Headlines

No Headlines